Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

GNPX
Genprex, Inc. Common Stock
stock NASDAQ

At Close
Jul 3, 2025 12:56:18 PM EDT
0.2600USD-2.889%(-0.0100)555,814
0.00Bid   0.00Ask   0.0000Spread
Pre-market
Jul 3, 2025 9:27:30 AM EDT
0.2613USD-3.222%(-0.0087)51,989
After-hours
Jul 2, 2025 4:58:30 PM EDT
0.2613USD-2.141%(-0.0057)0
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 27, 2022
11:26AM EST  Genprex' Highlights Preclinical Data For ONCOPREX Nanoparticle Delivery System In Treating Colon Cancer   Benzinga
11:23AM EST  Preclinical Data Show Potential for Use of Genprex's ONCOPREX(r) Nanoparticle Delivery System in Treating Colon Cancer   Business Wire
Jan 10, 2022
09:24AM EST  Genprex Announces Plan To Accelerate Opening Of Clinical Trial Sites For Acclaim-1 Trial   Benzinga
09:17AM EST  Genprex to Accelerate Opening of Acclaim-1 Clinical Trial Sites for REQORSA(tm) Systemic Gene Therapy in Non-Small Cell Lung Cancer   Business Wire
Jan 5, 2022
08:00AM EST  Genprex to Participate in January Investor and Healthcare Conferences to Highlight Company's Gene Therapies in Cancer and Diabetes   Business Wire
Jan 4, 2022
08:06AM EST  Genprex Expands Gene Therapy Oncology Pipeline To Include Small Cell Lung Cancer   Benzinga
Jan 3, 2022
09:13AM EST  The U.S. Food and Drug Administration has granted Fast Track Designation for Genprex Inc.'s (GNPX), lead drug candidate, REQORSA Immunogene Therapy, in combination with Merck & Co's Keytruda in patients with histologically-confirmed unresectable stage III or IV non-small cell lung cancer or NSCLC whose disease progressed after treatment with Keytruda.   RTTNews
08:11AM EST  Genprex Gets FDA Fast Track Designation For REQORSA Immunogene Therapy In Combination With Keytruda For NSCLC Treatment   RTTNews
08:03AM EST  Genprex Receives FDA Fast Track Designation For REQORSA Immunogene Therapy In Combination With Keytruda For Treatment Of Non-Small Cell Lung Cancer   Benzinga
08:00AM EST  Genprex Receives U.S. FDA Fast Track Designation for REQORSA(tm) Immunogene Therapy in Combination With Keytruda(r) for the Treatment of Non-Small Cell Lung Cancer   Business Wire
Nov 16, 2021
08:30AM EST  Genprex to Present in November CEO Roadshow Webinar   Business Wire
Sep 28, 2021
06:50AM EDT  Genprex Strengthens Management Team with Appointments of Industry Leaders Mark S. Berger, M.D. as Chief Medical Officer and Hemant Kumar, Ph.D. as Chief Manufacturing and Technology Officer   Business Wire
Sep 20, 2021
07:00AM EDT  Genprex to Participate in September Investor Conferences   Business Wire
Aug 17, 2021
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
Jul 20, 2021
08:30AM EDT  Genprex to Participate in a Monthly CEO Roadshow Webinar Series   Business Wire
Jul 16, 2021
07:37AM EDT  The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study   Benzinga
Jun 23, 2021
08:36AM EDT  Genprex:Phase 1/2 Acclaim-1 Trial Begun For REQORSA Immunogene Therapy With Tagrisso To Treat NSCLC Following FDA Review   RTTNews
08:31AM EDT  Genprex Announces Initiation Of Phase 1/2 Acclaim-1 Clinical Trial For REQORSA Immunogene Therapy In Combination With Tagrisso To Treat Non-Small Cell Lung Cancer Following FDA Review   Benzinga
08:30AM EDT  Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA(tm) Immunogene Therapy in Combination with Tagrisso(r) to Treat Non-Small Cell Lung Cancer Following FDA Review   Business Wire
May 19, 2021
08:30AM EDT  Genprex Announces Participation in Noble Capital Markets' Virtual Roadshow Series   Business Wire
May 14, 2021
01:01PM EDT  From BZ Small Cap Event: Genprex CEO Rodney Varner Says Co. Reviewing Additional Technologies For In-Licensing And Within Co.   Benzinga
12:56PM EDT  From BZ Small Cap Event: Genprex CEO Rodney Varner Says Program Is To Combine Gene Therapy With Two Of The Largest-Selling Drugs   Benzinga
12:52PM EDT  From BZ Small Cap Event: Genprex CEO Rodney Varner Begins Presentation   Benzinga
06:48AM EDT  Schedule For Benzinga's Global Small Cap Conference Friday, May 14, 2021   Benzinga
May 13, 2021
08:26AM EDT  Benzinga Pro's Top 6 Stocks To Watch For Thursday, May 13, 2021 (BZ Small Cap Event Edition): UGRO, CANF, MYMD, OBLG, ELYS, GNPX   Benzinga
May 10, 2021
08:30AM EDT  Genprex to Participate in Upcoming May Investor Conferences   Business Wire
May 6, 2021
09:07AM EDT  Genprex Reports In-Licensing Of Added Gene Therapy Technologies For Treatment Of Lung Cancer   Benzinga
09:05AM EDT  Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer   Business Wire
May 5, 2021
08:56AM EDT  Genprex Announces Centralized Institutional Review Board Approval For Acclaim-1 Clinical Trial In Non-Small Cell Lung Cancer   Benzinga
May 4, 2021
09:33AM EDT  Genprex Says Initiates Site Recruitment For Acclaim-2 Clinical Trial For Treatment Of Non-Small Cell Lung Cancer   Benzinga
09:32AM EDT  Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer   Business Wire
Apr 21, 2021
08:37AM EDT  Genprex to Participate in CEO Roadshow Webinar Series   Business Wire
Apr 20, 2021
08:30AM EDT  Genprex to Receive Inaugural "License of the Year" Award from University of Pittsburgh Innovation Institute in Recognition of Advances Made with Gene Therapy Program in Diabetes   Business Wire
Apr 12, 2021
08:31AM EDT  Genprex Announces Its Collaborators Presented Preclinical Data For REQORSA Immunogene Therapy In Non-Small Cell Lung Cancer At 2021 AACR Annual Meeting   Benzinga
08:30AM EDT  Genprex Collaborators Report Positive Preclinical Data for REQORSA(tm) Immunogene Therapy in Non-Small Cell Lung Cancer at the 2021 AACR Annual Meeting   Business Wire
Apr 5, 2021
08:30AM EDT  Genprex to Present at the 2021 Virtual Cell & Gene Meeting on the Mediterranean   Business Wire
Mar 30, 2021
08:39AM EDT  Genprex Announces Preclinical Data For TUSC2 Immunogene Therapy in Non-Small Cell Lung Cancer To Be Featured In Two Presentations At 2021 American Association for Cancer Research Annual Meeting Apr. 9-14   Benzinga
08:37AM EDT  Genprex Reports Preclinical Data For TUSC2 Immunogene Therapy In NSCLC To Be Featured In Two Presentations   RTTNews
08:30AM EDT  Genprex Announces Preclinical Data for TUSC2 Immunogene Therapy in Non-Small Cell Lung Cancer to Be Featured in Two Presentations at the 2021 American Association for Cancer Research Annual Meeting   Business Wire
Mar 24, 2021
08:30AM EDT  Genprex to Present at the Spring 2021 Oncology Investor Conference on March 29   Business Wire
Mar 9, 2021
09:19AM EST  Genprex 8-K Shows Amendment To Patent, Technology License Deal With University Of Texas System For Added Portfolio Of 6 Patents, 1 Patent Application   Benzinga
Mar 1, 2021
08:30AM EST  Genprex to Participate in Upcoming March Investor Conferences   Business Wire
Feb 9, 2021
08:34AM EST  Genprex Announces $25 Mln Direct Offering   RTTNews
08:33AM EST  Genprex Prices 4M Share Offering At $6.25/Share   Benzinga
08:30AM EST  Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants   Business Wire
08:10AM EST  The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement   Benzinga
Feb 8, 2021
03:31PM EST  Genprex Announces Formation of Clinical Advisory Board   Benzinga
08:35AM EST  Small and Microcap Company Investor Presentations Now Available for On-Demand   PR Newswire
Feb 4, 2021
08:30AM EST  Genprex Recognizes World Cancer Day   Business Wire
Feb 1, 2021
01:30PM EST  Genprex Issues Shareholder Letter and Provides Corporate Update   Business Wire
Jan 28, 2021
08:35AM EST  Live Investor Conference & Webinar: Small and Microcap Company Showcase on   PR Newswire
Jan 27, 2021
08:30AM EST  Genprex to Present at the Virtual Investor Conference Small and Microcap Showcase on February 4   Business Wire
Jan 21, 2021
08:30AM EST  Genprex to Present its Cutting-Edge Gene Therapies at the MoneyShow Accredited Investors Virtual Expo   Business Wire
Jan 14, 2021
08:30AM EST  Genprex to Present at NobleCon17 on January 19   Business Wire
Jan 13, 2021
09:07AM EST  Genprex Says Achieves Major Manufacturing Milestone For REQORSAImmunogene Therapy For Upcoming Trials To Treat NSCLC   RTTNews
09:03AM EST  Genprex Says Has Met All Specifications And Passed All Of The Final Release Tests For Its First Scaled-Up Clinical-Grade Manufacturing Run Of REQORSA   Benzinga
09:00AM EST  Genprex Achieves Major Manufacturing Milestone for REQORSA(tm) Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer   Business Wire
Dec 29, 2020
10:19AM EST  Genprex's Leading Drug Candidate Is Currently Being Developed As A Treatment For Lung Cancer   Benzinga
Dec 28, 2020
10:02AM EST  Genprex 13G Filing From Altium Capital Shows 7.2% Stake In Co.   Benzinga
Dec 24, 2020
01:08PM EST  Genprex Announces Closing Of $12 Mln Registered Direct Offering   RTTNews
01:02PM EST  Genprex, Inc. Announces Closing Of $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Without Warrants   Business Wire
Dec 22, 2020
01:18PM EST  UPDATE: Genprex Offering Of 3.11M Shares At $3.85/Share   Benzinga
01:17PM EST  Genprex Reports $12M At-The-Market Offering   Benzinga
01:15PM EST  Genprex, Inc. Announces $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules, Without Warrants   Business Wire
12:11PM EST  Genprex's Leading Drug Candidate Is Currently Being Developed As A Treatment For Lung Cancer   Benzinga
09:40AM EST  Genprex Completes Manufacturing Scale-Up For Clinical-Grade Production Of REQORSA Immunogene Therapy   RTTNews
09:32AM EST  Genprex Completes Manufacturing Scale-Up for Clinical-Grade Production of REQORSA(tm) Immunogene Therapy for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials For Lung Cancer   Business Wire
Dec 9, 2020
09:06AM EST  From BZ Small Cap Event: Genprex Operating CEO Says Lung Cancer Is The Most Common Cancer With An Expected Global Market Of $26.3B By 2023   Benzinga
09:05AM EST  From BZ Small Cap Event: Genprex Operating CEO Says Co. Is Initiating Two Lung Cancer Trials In First Half Of 2021   Benzinga
09:05AM EST  From BZ Small Cap Event: Genprex Operating CEO Says Co. Has An FDA Fast Track Designation For The Use Of Gene Therapy "REQORSA" With "Tagrisso" From AstraZeneca   Benzinga
09:04AM EST  From BZ Small Cap Event: Genprex Operating CEO Says Co. Is Addressing A Large Market With An Unmet Need WHich A Target In Lung Cancer   Benzinga
09:04AM EST  From BZ Small Cap Event: Genprex Operating CEO Rodney Varner Says Co. Has Gene Therapy Platform That Delivers Therapeutic Genes To A Range Of Cancers And Can Be Combined With Other Therapies And Drugs   Benzinga
Dec 8, 2020
02:53PM EST  From BZ Small Cap Event: Genprex Operating CEO Says Lung Cancer Is The Most Common Cancer With An Expected Global Market Of $26.3B By 2023   Benzinga
02:49PM EST  From BZ Small Cap Event: Genprex Operating CEO Says Co. Has An FDA Fast Track Designation For The Use Of Gene Therapy "REQORSA" With "Tagrisso" From AstraZeneca   Benzinga
02:47PM EST  From BZ Small Cap Event: Genprex Operating CEO Says Co. Is Initiating Two Lung Cancer Trials In First Half Of 2021   Benzinga
02:46PM EST  From BZ Small Cap Event: Genprex Operating CEO Says Co. Has An FDA Fast Track Designation For The Use Of Gene Therapy "Recoursa" With "Tegreso" From AstraZeneca   Benzinga
02:42PM EST  From BZ Small Cap Event: Genprex Operating CEO Says Co. Is Addressing A Large Market With An Unmet Need WHich A Target In Lung Cancer   Benzinga
02:41PM EST  From BZ Small Cap Event: Genprex Operating CEO Rodney Varner Says Co. Has Gene Therapy Platform That Delivers Therapeutic Genes To A Range Of Cancers And Can Be Combined With Other Therapies And Drugs   Benzinga
08:17AM EST  Genprex Completes Manufacturing Technology Transfer For Novel Gene Therapy   Benzinga
Dec 7, 2020
05:22PM EST  Schedule Of NYSE-, Nasdaq-Listed Publicly-Traded Companies Presenting At Benzinga's Small Cap Conference Dec. 8-9   Benzinga
Dec 3, 2020
08:17AM EST  Genprex to Present at the Benzinga Global Small Cap Conference on December 8   Business Wire
Nov 30, 2020
02:07PM EST  Genprex Initiates Site Recruitment For Acclaim-1 Clinical Trial For Treatment Of Non-Small Cell Lung Cancer   Benzinga
Nov 24, 2020
08:16AM EST  Genprex to Participate at the Diamond Equity Research Emerging Growth Invitational on December 1   Business Wire
Nov 11, 2020
08:16AM EST  Genprex to Participate in Panel at Life Sciences Summit on November 17   Business Wire
Nov 10, 2020
08:20AM EST  Genprex Announces Addition Of George Gittes To Scientific Advisory Board   RTTNews
08:17AM EST  Genprex Strengthens Scientific Advisory Board with Appointment of Lead Researcher of University of Pittsburgh, George K. Gittes, MD   Business Wire
Oct 30, 2020
08:20AM EDT  Genprex Announces New Branding for Upcoming Combination Clinical Trials In Non-Small Cell Lung Cancer   Benzinga
08:17AM EDT  Genprex Unveils New Branding for Upcoming Combination Clinical Trials in Non-Small Cell Lung Cancer   Business Wire
Oct 29, 2020
08:26AM EDT  Genprex Receives Conditional FDA Acceptance of Proprietary Name REQORSA for Lead Drug Candidate for Treatment of Non-Small Cell Lung Cancer   Benzinga
08:22AM EDT  Genprex Receives Conditional FDA Acceptance Of Proprietary Name REQORSA For Lead Drug Candidate For NSCLC Treatment   RTTNews
08:16AM EDT  Genprex Receives Conditional FDA Acceptance of Proprietary Name REQORSA(tm) for Lead Drug Candidate for Treatment of Non-Small Cell Lung Cancer   Business Wire
Oct 26, 2020
08:18AM EDT  Genprex Promote Eric Chapdelaine To VP Of Manufacturing   RTTNews
08:16AM EDT  Genprex Promotes Eric Chapdelaine to Vice President of Manufacturing   Business Wire
Oct 7, 2020
08:17AM EDT  Genprex to Present at Zooming with LD Micro on October 14, 2020   Business Wire
Oct 6, 2020
08:16AM EDT  Genprex to Present at the Alliance for Regenerative Medicine's Virtual Cell and Gene Meeting on the Mesa   Business Wire
Sep 21, 2020
08:22AM EDT  Genprex Appoints Thomas Gallagher As SVP Of Intellectual Property And Licensing   RTTNews
08:17AM EDT  Genprex Names Seasoned IP Executive, Thomas C. Gallagher, as Senior Vice President of Intellectual Property and Licensing   Business Wire
Sep 2, 2020
08:20AM EDT  Genprex Appoints William Gannon, Jr. As VP Of Regulatory Affairs   RTTNews
08:17AM EDT  Genprex Appoints William E. Gannon, Jr., MD, MBA, as Vice President of Regulatory Affairs   Business Wire
Aug 26, 2020
08:17AM EDT  Genprex to Present at The LD 500 Virtual Conference   Business Wire
Jul 31, 2020
08:26AM EDT  Genprex Shares Higher In Premarket On Very Light Volume Following Co. Press Release Will Present At Proactive's One2One Virtual Investor Forum On Aug. 4   Benzinga
08:17AM EDT  Genprex to Present at Proactive's One2One Virtual Investor Forum on August 4, 2020   Business Wire
Jul 30, 2020
08:16AM EDT  Genprex CEO Participates in a Second-Round Live Interview on the "Big Biz Show"   Business Wire
Jul 21, 2020
08:20AM EDT  National Institute Of health Awards Research Grant of $2.59M To University Of Pittsburgh For Diabetes Gene Therapy Technology Licensed By Genprex   Benzinga
08:18AM EDT  National Institutes Of Health (NIH) Awards Research Grant Of $2.59M To University Of Pittsburgh For Diabetes Gene Therapy Technology Licensed By Genprex   Benzinga
08:17AM EDT  National Institutes of Health (NIH) Awards Research Grant of $2.59 Million to University of Pittsburgh for Diabetes Gene Therapy Technology Licensed by Genprex   Business Wire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC